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a b s t r a c t
In the fields of pharmaceutical research and biomedical sciences, QSAR modeling is an estab-
lished approach during drug discovery for prediction of biological activity of drug candidates. Yet,
QSAR modeling poses a series of open challenges. First, chemical compounds are represented on a
high-dimensional space and thus feature selection is typically applied, although this task entails a
challenging combinatorial problem with potential loss of information. Second, the definition of the
applicability domain of a QSAR model is a desirable aspect to determine the reliability of predictions
on unseen chemicals, which is often difficult to assess due to the extent of the chemical space. Finally,
interpretability of these models is also a critical issue for drug designers. The purpose of this work
is to thoroughly assess the application of neural-based methods and recent advances deep learning
for QSAR modeling. We hypothesize that neural-based methods can overcome the need to perform a
descriptor selection phase. We developed three QSAR models based on neural networks for prediction
of relevant chemical and biomedical properties that, in the absence of any feature selection step,
can outperform the state-of-the-art models for such properties. We also implemented an embedded
applicability domain technique based on network output probabilities that proved to be effective; its
application improved the predictive performance of the model. Finally, we proposed the use of a post
hoc feature analysis technique based on an aggregation of network weights, which enabled effective
detection of relevant features in the model.
© 2019 Elsevier B.V. All rights reserved.
1. Introduction
The integration of computational sciences into the pharma-
ceutical and biomedical industry has yielded several applications
and technological advances during the last decades [1,2]. The
pharmaceutical industry is primarily headed towards improving
the long and costly process of discovery and development of
new drugs, which involves several stages including in vitro and
in vivo wet-lab experiments. Computer-aided rational drug de-
sign has allowed accelerating drug candidate identification and
prioritization while reducing costs and has helped improve the
critical attrition rate in drug discovery projects [3,4]. The purpose
of in silico drug discovery is to design models for predicting
biological activity and physicochemical properties of drug can-
didate compounds. These models, referred to as Quantitative
Structure-Activity Relationship (QSAR), are regression or clas-
sification models used in chemical and biological sciences to
predict the relationship between features encoding the molecular
∗ Corresponding author at: Department of Computer Science and Engineering,
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structure of compounds and the target property or biological
activity under study. QSAR models are extensively used for vir-
tual screening and prediction of categorical properties of drug
candidates [5].
The development of QSAR models generally involves dealing
with high-dimensional data representations. Drug candidates can
be described by a large number of features or descriptors, which
encode structural properties of the molecules. Feature selection
is usually applied prior to the development of a QSAR model in
order to harness high dimensionality [6,7], and mostly because
traditional machine learning techniques do not perform properly
in this high-dimensional scenario [8]. However, considering the
large variety of possible descriptors that can be calculated from
compounds, feature selection represents a difficult combinatorial
problem that may neglect valuable information.
Another important aspect of QSAR modeling is determining
the reliability of predictions on unseen compounds. The Appli-
cability Domain (AD) of a QSAR model is the molecular subspace
where predictions performed by the model are expected to be
accurate. AD analysis is a significant step in the process of build-
ing a reliable QSAR model [9] and the identification of the AD
of a QSAR model remains a current matter of research [10,11].
https://doi.org/10.1016/j.asoc.2019.105777
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A last important aspect of QSAR modeling is interpretability, as
such models are managed by medicinal chemists in the process
of searching for drug candidates. Being able to gain insight into
the features that are the most relevant for prediction is valuable
for experts [12], as such interpretation makes it possible to un-
derstand the molecular substructures that play a significant role
in the biological activity or property of the chemical compound.
Regarding the techniques that have been used for QSAR mod-
eling, two of them stand out. On the one hand, the use of meta-
classifiers and consensus approaches has been widespread in
QSAR modeling, and these methods have become the state of the
art for predicting several physicochemical properties and biologi-
cal activities [13,14]. On the other hand, artificial neural networks
– a bio-inspired technique [15] – have also been used for QSAR
modeling, although their adoption has been criticized due to
their lack of generalization and the difficulty in the interpreta-
tion of such models in physicochemical terms [16]. Moreover,
in recent years QSAR modeling has witnessed the advent of
deep learning, which has brought several advantages as well
as challenges. Recent advances in Deep Neural Network (DNN)
approaches have made neural models less prone to overfitting,
and hence more likely to be applied successfully for predicting
unseen compounds. In addition, DNN-based models have been
found effective for solving large-scale and high-dimensional data
analysis problems [17].
The goals of this work are to build QSAR models that incor-
porate recent advances in deep neural networks for prediction of
three relevant properties in biomedical sciences, and to bench-
mark these models against the state of the art. In addition, we
aim to explore the potential of applying confidence estimation
to neural-based models as an effective way for AD assessment,
as well as to study the possibility to interpret these models in
terms of the molecular features used to represent the chemical
data. In order to address these goals, we propose the devel-
opment of neural-based QSAR models for bioactivity prediction
of three different properties. On these models, we evaluate the
network output probabilities as a means of performing an AD
estimation. In addition, we provide a post-hoc analysis of the
most relevant features for each property. The first two proper-
ties are Cytochrome P450-drug interaction for isoforms 2C9 and
3A4, which are a family of enzymes involved in the oxidation
of compounds. These two isoforms are particularly relevant to
drug metabolism. It has been proven that inhibition of CYP en-
zymes leads to adverse side effects of drug–drug interactions [18],
and hence the study of CYP interactions has become of major
interest in the fields of drug discovery. The third property is
Ready Biodegradability (RB). Biodegradation is highly relevant
to biomedical sciences, since the presence of certain substances
persisting over an extended period of time has been linked to
major health risks, such as cancers, neurological dysfunction and
hormonal changes [19,20]. Biodegradation properties are also
relevant in the design of polymeric materials used for biomedical
purposes [21]. Therefore, predicting biodegradability properties
on chemicals represents a critical aspect for several biomedical
areas.
The contributions of this work can be summarized as follows:
• We applied recent advances in deep neural networks to the
development of neural-based QSAR models and obtained
higher performance compared to state-of-the-art models,
while at the same time overcoming the need for a poten-
tially detrimental feature selection phase.
• We proved the effectiveness of using network output prob-
abilities to perform AD estimation, which represents an
advancement over consensus-based AD models that merely
provide a binary signal with regard to inclusion or exclusion
in the applicability domain.
• We applied a post hoc interpretability method based on an
analysis of the network weights that has never been applied
before in the context of QSAR models. We presented the re-
sults by means of a novel visualization based on heat maps,
and proved that it effectively allows to gain insight into the
interpretability of the proposed neural-based models.
• Our models outperformed the current state of the art for
three different properties of high relevance in biomedical
sciences.
This paper is organized as follows: in Section 2 we conduct
a survey on relevant articles in the area and how they relate to
our work. In Section 3, the datasets used for our experiments as
well as the proposed methods are detailed. We present the results
obtained for our proposed models and discuss their implications
in Sections 4 and 5. Finally, conclusions and future lines of work
are presented in Section 6.
2. Related work
For the past decades the process of rational drug design has
relied on computer modeling techniques, and various in silico
methods have been widely applied with the aim of both speeding
up the discovery process and reduce costs [22–24]. Traditional
techniques, such as Support Vector Machines (SVM), Decision
Trees, Naïve Bayes and k-Nearest Neighbors, have been exten-
sively used for building QSAR models because of their relatively
good performance and simplicity [25–27]. Recently, there has
been a strong tendency to consensus-based approaches, which
consist in assembling different base classifiers to combine their
predictions and, as a consequence, increase the prediction capa-
bilities of the model [28–32]. This type of models are typically
among the top performing techniques for the prediction of sev-
eral chemical properties in QSAR modeling , but at the expense
of limited interpretability. Besides, they are constrained by their
base models, which usually rely on a feature selection step in
order to perform at their best [33,34], and they are normally not
able to capture complex relationships between descriptors or rule
out redundant information [28,35].
2.1. Prediction techniques for Cytochrome P450-drug interaction
and ready biodegradability
Extensive research work has been carried out for predicting
Cytochrome P450-drug interaction, and the majority of these
works usually involve a feature selection process [36–38]. Jensen
et al. [36] presented two Gaussian kernel weighted k-Nearest
Neighbors models. It was the first work to incorporate the use of
Extended Connectivity Fingerprints (ECFP) and Functional Class
Fingerprints (FCFP) [39] as features for CYP2D6 and CYP3A4 in-
hibition prediction. Cheng et al. [37] developed consensus-based
models for prediction of five different CYP isoforms, using SVM,
C4.5 Decision Tree, k-Nearest Neighbors and Naïve Bayes as base
classifiers, combined by a backpropagation artificial neural net-
work. they also showed an AD estimation that improves pre-
diction accuracy. More recently, Shah et al. [38] developed a
joint QSAR model based on feed-forward multi-layer neural net-
works for prediction of drug metabolism of isoforms 3A4, 2C9
and 2D6 of Cytochrome P450. Fingerprints were used as input
features, and the three biological activities were embedded in
a multitask deep neural network. Nembri et al. [40] developed
two consensus-based models for prediction of isoforms 3A4 and
2C9 inhibition, and also performed an AD analysis. Both of the
reported models were constructed upon two different voting
approaches and used variations of k-Nearest Neighbors and a
classification tree as base classifiers. Each base classifier was con-
structed employing either ECFP or a small number of molecular
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descriptors obtained from a two-phase feature selection process.
The best performing model reported for isoforms 2C9 and 3A4
was one of the voting approaches (namely Consensus 1). Since
the work by Nembri et al. [40] reports one of the best prediction
performances of biological activity for Cytochrome P450 and also
due to the provision of all the data necessary for reproducibility,
it constitutes the reference research work on CYP inhibition that
we use for comparison.
There are also several research studies for prediction of both
Biodegradability and Ready Biodegradability of compounds [10,
41–45], where two main approaches stand out: consensus and
neural-based models. Consensus models are predominant for the
prediction of this property, where feature selection techniques
are applied in most cases [41,42,44,46]. Involving neural-based
techniques, Goh et al. [45] developed a multimodal architec-
ture for biodegradability prediction combining a Convolutional
Neural Network with a fully-connected multi-layer perceptron,
and using both domain-specific hand-engineered features and
learned representations from raw data. In Mansouri et al. [41],
two consensus models were proposed for prediction of Ready
Biodegradability of compounds over three different base classi-
fiers: Partial least Squares Discriminant Analysis (PLS-DA), SVM
and k-Nearest Neighbors. The proposed consensus models were
based on two different voting approaches and an AD analysis
was carried out on the developed QSAR models. The best voting
approach Consensus 2 is reported as the best predictive model,
which represents the best classification performance compared
to other published QSAR models on biodegradation, and thus we
chose this work Mansouri et al. [41] as our reference method for
comparison.
Deep learning has emerged in the last years as a widely used
soft-computing technique for the development of QSAR models
and other areas in drug discovery research, and it has established
itself as the state-of-the-art prediction technique [3,47]. Although
artificial neural networks have already been used for QSAR mod-
els in the past [24,48], there is a recent tendency to adopt new
strategies for training neural-based models, such as the appli-
cation of novel techniques for avoiding overfitting and vanish-
ing/exploding gradients during training. Although the application
of deep learning in QSAR modeling is still in its beginnings, sev-
eral research studies have developed deep learning-based models
for various drug discovery problems successfully [49–51]. In Ma
et al. [49], models based on DNNs achieved higher prediction
performance than Random Forest on a group of large and diverse
QSAR datasets. Lenselink et al. [50] compared five different tech-
niques over a ChEMBL bioactivity benchmark set and found that
DNNs outperformed traditional methods. They also showed that
an ensemble of DNNs with additional tuning further improves the
performance obtained by more simple DNN-based models. Kout-
soukas et al. [51] showed that DNN-based models statistically
outperform models based on traditional methods, such as Naïve
Bayes, k-Nearest Neighbors, SVM and Random Forest over diverse
datasets.
2.2. Applicability domain and interpretability of prediction models
The determination of the applicability domain of a QSAR
model is a crucial aspect of the modeling process, since it allows
to determine the molecular subspace of compounds where the
QSAR model is expected to make reliable predictions [10,52].
Most research articles in the area address AD determination using
a standalone method, where different strategies and statistical
measures are adopted to determine AD boundaries [10]. A good
number of them focus on defining different molecular similarity
criteria for identifying outliers, which are then excluded from the
AD of the model [53–55]. Klingspohn et al. [10] performed a com-
prehensive study in order to define a taxonomy of AD methods
and find the best approaches for estimating the AD of different
classification methods. In this article, two main categories of
techniques for determining the AD were identified and compared:
those based on novelty detection (identification of outliers) and
those based on confidence estimation (inferred from the trained
classifier). Experiments using six different binary classification
techniques on ten datasets were performed. It was concluded
that AD measures based on confidence estimation consistently
perform better than novelty detection techniques, and thus they
are suitable approaches for defining the AD.
Since QSAR models are meant to assist experts during drug
discovery, their results should be as interpretable as possible [56].
Consensus-based approaches, in spite of having good predictive
performance, tend to lack interpretability since their output result
is a combination of different base classifiers. Interpretability of
neural network-based models has been studied for several years
within the machine learning community [57–59] and it also re-
mains a matter of research in drug discovery. Approaches based
on post hoc interpretability have been explored recently [60–
62]. This type of techniques takes a trained model and makes an
attempt to understand predictions in terms of the features used
by the model. As opposed to a low-level algorithmic comprehen-
sion of the model, which is the most usual approach taken for
interpretability analysis, post hoc techniques aim to characterize
the behavior of the predictive model without attempting to ex-
plain its internal representation and operations, but providing a
functional understanding of it in terms of its features. In this line
of work, Tsang et al. [63] developed a framework to discover sta-
tistical interactions between the input features in a feed-forward
multi-layer neural network, by direct interpretation of its learned
weights. Their method proved to be effective on both synthetic
and real-world application datasets, and thus we chose it as our
reference paper for post hoc feature analysis.
2.3. Our proposal
Based on the observed limitations and the current state of
the art, we propose the development of neural-based methods
to model three physicochemical properties, namely: Cytochrome
P450-drug interaction for isoforms CYP2C9 and CYP3A4, and
Ready Biodegradability. We compare our approach with the con-
sensus models that, to the best of our knowledge, represent the
top-performing models that have been published for the predic-
tion of these properties. We present an embedded applicability
domain technique, which is derived from our trained models. This
approach would be categorized as prediction confidence estima-
tion according to Klingspohn’s taxonomy [10]. We propose the
application of a post hoc interpretability technique based on an
aggregative analysis of the weight contributions of the network,
which is based on Tsang et al. [63]. To the best of our knowledge,
this method has not yet been employed for interpretability of
QSAR models. Additionally, the results of this post hoc analysis
are summarized using a novel visualization based on heat maps.
Finally, our models and results are contrasted to those reported
in Nembri et al. [40] and Mansouri et al. [41]. The reason for
choosing these latter articles as our baselines for comparison is
due to the possibility of reproducing their data and experiments
and the high performance attained in the reported results.
The entire workflow of our approach is depicted in Fig. 1.
First, we preprocessed the three datasets under study (a). Second,
we enriched the Original datasets by adding new molecular de-
scriptors (b) and we split the Enriched and Original datasets into
the partitions for training and validating our models (c). Then,
we developed our neural-based models by performing an itera-
tive process for hyperparameter tuning and we train the chosen
models (d). Next, we evaluated their performance using several
4 M.V. Sabando, I. Ponzoni and A.J. Soto / Applied Soft Computing Journal 85 (2019) 105777
Fig. 1. Depiction of the entire workflow of our method: (a) data preprocessing, (b) dataset enrichment, (c) dataset partition, (d) development and training of models,
(e) evaluation of models, (f) AD analysis, (g) post hoc feature analysis.
metrics and we contrasted these results with different baselines
(e). Finally, we developed an AD model based on confidence
estimation and applied (f) a post hoc feature analysis method,
which allows to determine the most influential features to our
models (g).
3. Materials and methods
In this section, we provide an overall description of all the
techniques used in our work, as well as the preparation of the
datasets and the selection of the hyperparameters of the model.
We say that we enrich a dataset when we extend its set of
features by including new molecular descriptors not previously
considered in the Original dataset (Fig. 1-b). It is worth noting
that the included descriptors are members of the family of de-
scriptors already included in the Original datasets. The reported
partitions of the datasets in Train, Validation and Held-out sets1
were kept the same during the construction of our models (Fig. 1-
c). For the sake of completeness, we also trained our Best_E
models using 5-fold Cross Validation. The details of this process
and its results are summarized in the Supplementary Material.
All of our models are based on feed-forward multi-layer neural
networks. The architecture for each model varies depending on
the number of input features or molecular descriptors. As a gen-
eral approach, larger inputs demand more complex architectures,
so the Enriched versions of the datasets yielded models with
more nodes than those built for the Original versions of the
datasets. Our neural-based models were obtained following a
two-phase process (Fig. 1-d). The first one consisted in an ex-
ploratory phase, where different architectures and optimization
strategies were considered. In this phase we developed proto-
types and tuned their parameters. The need for an exploratory
phase when constructing neural networks has been reported pre-
viously in the context of QSAR modeling [64]. The second phase
consisted in selecting the best prototype from the first phase. This
selection was performed by assessing classification performance
on the Validation set. Due to the inherent stochasticity of neural
networks, we repeated the training process using a set of fifteen
random seeds for each dataset. As a result of this two-phase
1 Note that the Original datasets refer to these partitions in their papers as
Training, Test and External Validation, respectively.
process we obtained fifteen models with the same hyperparame-
ters but initialized differently. The average performance of these
fifteen models is reported as the Average model, whereas we
report as the Best model the one that performs the best on the
Validation set.
After the best model for each Enriched dataset was obtained,
we built a new model for the Original version of each dataset
– namely Best_O – using the same hyperparameters as for the
Enriched models but using less nodes per layer. The construction
of two models, one based on the Enriched dataset and another
based on the Original dataset, enable us to compare the perfor-
mance of our proposed strategy over one same set of compounds
with and without the application of a feature selection pro-
cess, and it allows to analyze the potential of our approach on
high-dimensional datasets.
3.1. Datasets
The three datasets used in this work, namely CYP2C9, CYP3A4
[40] and RB [41], are publicly available and were selected taking
into account their relevance in QSAR modeling in the context of
biomedical data analysis. We made datasets CYP2C9, CYP3A4 and
RB in their Enriched versions publicly available.2 Further informa-
tion on the calculation of molecular descriptors for the construc-
tion of the Enriched datasets can be found in the Supplementary
Material.
3.1.1. CYP2C9 and CYP3A4
Datasets CYP2C9 and CYP3A4 have a total of 11940 and 12118
compounds, and the proportion between active/inactive com-
pounds on their Training and Validation sets is 49/100 for CYP2C9
and 66/100 for CYP3A4. As for the Held-out sets, the ratios are
56/100 in CYP2C9 and 98/100 in CYP3A4. CYP2C9 and CYP3A4
share the same compounds in their Training sets as well as in
their Validation sets. In the Original datasets, CYP2C9 includes ten
molecular descriptors, whereas CYP3A4 includes eight molecular
descriptors. They also include a 1024-bit ECFP for each com-
pound [39]. For the Enriched versions of both datasets we added
a total of 2701 molecular descriptors to the CYP2C9 dataset and
2699 molecular descriptors to the dataset CYP3A4, leading to a
2 https://github.com/VirginiaSabando/DNN-QSAR-2019.git.
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total of 2711 and 2707 descriptors, respectively, in addition to
the 1024-bit ECFP. We performed the calculation of molecular
descriptors and ECFP using Dragon 7 [65].
There were a few compounds on the datasets provided by
Nembri et al. [40] whose SMILES codes were not properly formed,
and hence we were unable to calculate their molecular descrip-
tors. As a result, one molecule was removed from both Train-
ing sets, six molecules were removed from the Held-out set of
CYP2C9, and one molecule was removed from the Held-out set of
CYP3A4.
3.1.2. Ready biodegradability (RB)
Dataset RB comprises 1725 compounds, where the ratio be-
tween active/inactive compounds is 51/100 for the Training set,
49/100 for the Validation set and 40/100 for the Held-out set.
A total of 41 molecular descriptors were provided for dataset
RB in its Original form. We calculated additional molecular de-
scriptors to obtain its Enriched version, which gave a total of
1480 molecular descriptors. We computed these descriptors us-
ing Dragon 7 [65].
3.2. Model parameterization
In this section, we describe all the model parameters used for
the three Enriched datasets. Parameters for the remaining models
and their training can be found in the Supplementary Material.
The models were built using Tensorflow 1.7 [66].
The input features for our predictive models were molecular
descriptors and ECFP. In the cases of CYP2C9 and CYP3A4, we split
the ECFP into 1024 separate bits and then considered each one
of these bits as a single input feature. All nodes in the input and
hidden layers of the models use rectified linear units (ReLU) as ac-
tivation function [67], and the output layer implements a softmax
function, which has two nodes for each class output probability.
The networks were trained using standard backpropagation [68]
and we chose a minibatch size of 200 instances to train the
networks. We use cross-entropy with logits as cost function and
Adam optimizer [69] for minimizing it.
For weight initialization we experimented with Xavier initial-
ization [70] and He Normal initialization [71], which are both
considered state-of-the-art initialization techniques [72,73]. We
also applied Batch Normalization [74] in all layers of our networks
for faster training and to avoid exploding/vanishing gradients.
In order to avoid overfitting, several regularization techniques
were used in each model. We used Dropout [75] with varying
dropout rates according to the number of nodes in each layer,
and also implemented L2-regularization [76] varying the penal-
ization coefficient λ in each model. We applied early stopping to
avoid overtraining the models, hence helping to prevent possible
overfitting.
The QSAR model obtained for Enriched dataset CYP2C9 is a
feed-forward multi-layer neural network architecture consisting
of one input layer of 3735 nodes (for 2711 molecular descriptors
plus 1024 bits from ECFP) and three hidden layers of 50, 20 and
5 nodes, respectively. Batch Normalization was applied with a
decay value of 0.9 to prevent the weights from growing too large,
and we used a learning rate value of 0.00001. We initialized the
network weights by using Xavier initialization. A penalization
coefficient λ = 0.0001 was used for L2-regularization. In order to
deal with class imbalance we optimized a weighted cost function,
which penalized mispredicted instances from the least popular
class by increasing the loss by a factor proportional to the class
imbalance observed in the Training set.
The architecture of the QSAR model that we developed for En-
riched dataset CYP3A4 is similar to that used for CYP2C9, with the
difference that the input layer consists of 3731 nodes (for 2707
molecular descriptors plus 1024 bits from ECFP). As in the case of
dataset CYP2C9, all layers implement Batch Normalization with
a decay value of 0.9. For CYP3A4, we initialized network weights
by applying He Normal initialization, and the same regularization
criteria than for CYP2C9 was taken into account for this dataset.
For class imbalance mitigation we applied a stratified sampling
technique, where an equal number of compounds belonging to
each class was drawn to build each of the minibatches during
training. The compounds were sampled with replacement from
the training set and randomly shuffled before they were fed to
the network during the training phase.
Lastly, we developed a QSAR model for Enriched dataset RB
based on a less dense feed-forward multi-layer neural network
architecture, considering that the input features were fewer than
those in the previously described models. The input layer com-
prises 1480 nodes for molecular descriptors, and the network is
also made of three hidden layers of 20, 10 and 5 nodes, respec-
tively. All layers implement Batch Normalization with a decay
value of 0.9, as in the case of the previous models. We initial-
ized the network weights by using Xavier initialization, and as
regularization techniques we used Dropout and L2-regularization
with a penalization coefficient λ = 0.001. The learning rate was
set to 0.0001. We used a stratified sampling technique in order
to counteract class imbalance, with the same sampling technique
as described in the case of CYP3A4.
3.3. Applicability domain
The applicability domain (AD) of a QSAR model is the molec-
ular subspace in which the predictions made by the model are
expected to be accurate [77,78]. In other words, the definition of
an AD allows the expert to determine whether a prediction on a
new compound is likely to be reliable or not.
We propose using class probability provided by the output
layer of our models to estimate their AD. This leads to AD models
which are embedded into the prediction models. The embedded
AD models were evaluated as follows. First, we computed class
probability values using the network softmax layer for every
compound. Then, we sorted these values in decreasing order to
elaborate a ranking. Finally, in order to evaluate the goodness of
the ranking of confident predictions, we computed Mean Average
Precision (MAP) [79], where several metrics (Accuracy, NER, etc.)
were calculated on the k-highest ranked compounds, where k is
varied from 1 to n, and n being the total number of compounds.
All these different metrics computed for different number of
compounds are averaged. This AD approach (Fig. 1-f) allows to
evaluate the performance of the models at any desired threshold
of membership to the AD.
3.4. Post hoc feature analysis
As QSAR models are tools for the benefit of chemists and drug
developers alike, it remains an important asset to provide means
of interpretability for any proposed models [56,80]. For domain
specialists it is useful to know the features that make a particular
family of compounds to show some degree of activity regarding a
property of interest, since this allows to reduce the search space
during drug discovery.
We propose a post hoc feature analysis technique as a way
of providing interpretability to our neural-based models, so that
domain experts can determine the most relevant molecular de-
scriptors in the context of a prediction model (Fig. 1-g). By analyz-
ing the network weight contributions in an aggregative manner,
it is possible to gain insight into the descriptors that are more
influential on the predicted target value.
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The proposed post hoc feature analysis technique is described
as follows: once training is completed, we calculate a score for
every descriptor by taking into account the sequence of contri-
butions from the input to the output nodes. For a given feature,
these contributions are calculated by aggregating the weights
of the neural model that are connected to this feature. More







which is the average of the k products between the weights
connecting node j with the k nodes in the following layer and
their scores. Given that this is a recursive definition, by setting
the score corresponding to the node of the output layer to 1,
we can compute all node scores by starting from the output
nodes and going backwards until the scores corresponding to the
input nodes are computed. We considered the absolute values
of the weights, as a way to analyze quantitative impact of the
descriptors on the output, regardless of whether they contribute
in a positive or negative manner on the result. The rationale is
that input features exhibiting high scores are likely to be more
relevant than those showing low scores, as slight changes in their
values would have greater impact on the outcome of the network.
4. Results
We performed an evaluation of each of our models by com-
paring them against Consensus 1 and Consensus 2, which are the
top-performing methods ever reported for the three datasets un-
der study [40,41] (Fig. 1-e). To account for a fair comparison, we
used the same metrics as reported in Nembri et al. [40],Mansouri
et al. [41], i.e., Sensitivity (Sn), Specificity (Sp) and NER, as well as
Accuracy (Acc) and MAP, as described in Section 3.3. Sensitivity
and Specificity quantify the accuracy in predicting the active and
inactive class, respectively, while NER is the arithmetic mean of
Sn and Sp. Additionally, other performance metrics can be found
in the Supplementary Material.
Since our neural-based models are inherently stochastic, fif-
teen different trials were run to train and test the models, each
one using a different random seed. Therefore, we report both
the average performance of the developed models, i.e., taking
into account all trials, and the best performance in terms of NER,
i.e., the model obtained from the best seed.
Regarding the AD analysis, we report both NER and the per-
centage of compounds that are not within the AD – which are
referred to as Not Assigned compounds (%na) – as it was also done
by Nembri et al. [40] and Mansouri et al. [41]. We report NER
when %na is fixed to the value of the best reported method in the
referenced articles. Similarly, we report %na when NER is fixed to
the same values reported in the referenced papers.
4.1. CYP2C9
The results for the Original and Enriched versions of CYP2C9
are presented in Table 1. We also include the results of the best
model reported by Nembri et al. [40], i.e., Consensus 1. It can be
seen that for both Validation and Held-out sets our best Enriched
model, namely Best_E, performs better than the best model on
the Original dataset, namely Best_O, and both of them outperform
Consensus 1. In addition, all of our models achieve equivalent or
better NER values than Consensus 1when keeping %na at the same
value.
A more comprehensive evaluation of the performance of our
models on the CYP2C9 Held-out set is presented in Figs. 2 and 3.
Table 1
Results on the Validation and Held-out sets of CYP2C9. Consistently with the
results reported by Nembri et al. [40] the percentage of not assigned compounds
(%na) was set to 40% for Validation set, and 45% for Held-out set.
CYP2C9 Validation set Held-out set
NER Sn Sp Acc NER Sn Sp Acc
Original
Consensus 1 0.89 0.89 0.88 – 0.83 0.85 0.82 –
Average_O 0.91 0.90 0.92 0.91 0.83 0.79 0.88 0.86
Best_O 0.92 0.92 0.92 0.92 0.85 0.82 0.87 0.86
Enriched Average_E 0.92 0.93 0.91 0.92 0.85 0.87 0.83 0.84Best_E 0.93 0.94 0.93 0.93 0.87 0.89 0.86 0.87
Table 2
Results on the Validation and Held-out sets of CYP3A4. Consistently with the
results reported by Nembri et al. [40] the percentage of not assigned compounds
(%na) was set to 36% for Validation set, and 42% for Held-out set.
CYP3A4 Validation set Held-out set
NER Sn Sp Acc NER Sn Sp Acc
Original
Consensus 1 0.88 0.92 0.83 – 0.80 0.89 0.70 –
Average_O 0.89 0.83 0.94 0.91 0.82 0.76 0.88 0.83
Best_O 0.91 0.91 0.91 0.91 0.83 0.84 0.82 0.83
Enriched Average_E 0.92 0.89 0.94 0.92 0.84 0.84 0.85 0.84Best_E 0.93 0.91 0.94 0.93 0.85 0.86 0.84 0.85
These figures show different performance measures when differ-
ent cutoff values for the AD are considered. In Fig. 2 we present
the mean of all trials—i.e., Average performance, whereas in Fig. 3
the results for the best trial are presented. Both figures corre-
spond to the models trained on the Enriched version of CYP2C9.
The horizontal axis represents the number of compounds sorted
by class probability, so that the left-most compounds are the most
confidently predicted ones. The vertical axis represents different
performance measures evaluated over the set.
By looking at these plots it is possible to set any cutoff point
in the horizontal axis in order to evaluate performance when the
compounds with least certain prediction – those to the right of
the cutoff point – are discarded. In particular, two cutoff points
are marked as noteworthy; these are the cutoff values where %na
and NER match with the ones reported by Nembri et al. [40]. MAP
results for the Validation sets of the three datasets can be found
in the Supplementary Material.
4.2. CYP3A4
We present the results for CYP3A4 in Table 2. For both Val-
idation and Held-out sets our best Enriched model show better
performance than the best model trained on the Original version
of the dataset, which in turn overcomes the results reported for
Consensus 1. All of our models obtain higher Non-Error Rate for
the same number of discarded compounds than the reference
model, yet ours exhibiting balanced values of Sensitivity and
Specificity.
The plots showing the comprehensive performance of the
QSAR models with regard to its AD model for CYP3A4 Held-
out set are presented in Figs. 4 and 5. Similarly as it was done
for CYP2C9, Fig. 4 shows the results for the mean of all of our
trials, while Fig. 5 reports the results when our best model is
considered.
4.3. Ready biodegradability
Table 3 shows the results for RB. Our best Enriched model,
i.e., Best_E, exhibits higher NER in both Validation and Held-out
sets than Best_O, our best model trained on the Original dataset.
Both of these models show higher NER values than for Consensus
2.
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Fig. 2. Average MAP performance of all trials on the Held-out set of Enriched CYP2C9. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
Fig. 3. MAP performance of the best trial on the Held-out set of Enriched CYP2C9. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
Fig. 4. Average MAP performance of all trials on the Held-out set of Enriched CYP3A4. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
The plots displaying the performance of the QSAR models with
regard to its AD model for the Enriched model on the RB Held-out
set are presented for the mean of all of our trials (Fig. 6), and for
the best trial, i.e., Best_E (Fig. 7).
4.4. Post hoc feature analysis
We performed a post hoc feature analysis in order to gain in-
sight on which molecular descriptors are the most relevant to our
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Fig. 5. MAP performance of the best trial on the Held-out set of Enriched CYP3A4. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
Fig. 6. Average MAP performance of all trials on the Held-out set of Enriched RB. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
Fig. 7. MAP performance of the best trial on the Held-out set of Enriched RB. (a) NER and Accuracy are shown. (b) Sensitivity and Specificity are shown.
models. We propose a novel visualization for summarizing main
patterns of features that were found to be relevant across multi-
ple trials by means of a heat map. The heat maps that encode the
results corresponding to the feature analysis for datasets CYP2C9,
CYP3A4 and RB are presented in Figs. 8–10, respectively. Each
row corresponds to a different trial of our model using its own
seed for initialization of weights and random variables. These
trials are sorted by performance, where the top row represents
the best trial. Each column on the maps represents molecular
descriptors, where only the 20 most relevant descriptors of each
model according to our measure were considered. Descriptors
marked with an asterisk are also part of the Original version
of the dataset. Descriptor names starting with ‘ECFP’ represent
Extended Connectivity Fingerprint fragments, which are followed
by a number that represents the location of the bit that was
identified by our method as relevant. The rank that a descriptor
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Table 3
Results on the Validation and Held-out sets of Ready Biodegradability (RB).
Consistently with the results reported by Mansouri et al. [41] the percentage
of not assigned compounds (%na) was set to 15% for Validation set, and 13% for
Held-out set.
Ready Biodegradability (RB) Validation set Held-out set
NER Sn Sp Acc NER Sn Sp Acc
Original
Consensus 2 0.91 0.88 0.94 – 0.87 0.81 0.94 –
Average_O 0.92 0.94 0.90 0.91 0.88 0.85 0.91 0.90
Best_O 0.91 0.91 0.91 0.91 0.88 0.85 0.92 0.90
Enriched Average_E 0.94 0.93 0.90 0.94 0.88 0.83 0.93 0.90Best_E 0.94 0.95 0.92 0.93 0.89 0.85 0.93 0.91
occupies in the relevance order of a particular trial is encoded
with the number inside the corresponding heat map cell. Like-
wise, darker colors are applied to cells depicting higher relevance
descriptors in a specific trial, whereas lighter colors apply to less
relevant descriptors.
5. Discussion
In this section, we review the results presented previously in
Section 4. We discuss the performance of the models, as well
as the results of our embedded AD model and post hoc feature
analysis technique.
5.1. Neural-based classifiers versus consensus-based classifiers
As it is shown in Table 1, our models for prediction of CYP2C9
drug interaction outperform the results reported by Nembri et al.
[40]. The NER values of Average_E and Average_O are consistently
superior to the reference results. On the internal Validation set
of CYP2C9, the average Sn and Sp values in both the Original
and the Enriched version of the dataset are higher and more
balanced than those achieved by Consensus 1, which indicate that
our model has successfully overcome the class imbalance of the
dataset as it was able to correctly predict both active and inactive
compounds with similar accuracy. When evaluated on the Held-
out set of CYP2C9, our models also improve the performance
of the reference results, although the differences between our
models and Consensus 1 are smaller than those obtained on the
Validation set. Cohesively, a mild imbalance between Sn and Sp is
observed, which is consistent with the results reported by Nembri
et al. [40] on the Held-out set. The best trial on the Enriched
version of the CYP2C9 dataset, i.e.,Best_E, attained a NER value
of 0.93 for the internal validation set and a value of 0.87 when
tested on the Held-out set, which is an improvement of 0.04 over
the same results for Consensus 1.
In Table 2 the predictive performance of our models exceed
the results reported using Consensus 1. Similarly to what it was
observed for CYP2C9, the average NER of our models is higher
than that reported for Consensus 1 in the Original and Enriched
versions of the dataset, while also showing balanced results be-
tween Sn and Sp average values. On the Enriched Held-out set,
while the predictive performance slightly decreases compared to
the results on the Validation set, balanced results between Sn
and Sp values are obtained. This observation does not hold for
the average results in the Original version of the dataset. It is
worth noticing that average results were computed by taking into
consideration all trials of the model, including those undertrained
due to the model apparently getting caught on local minima. In
a similar way as it happened for CYP2C9, Best_E obtained the
highest NER for both the internal validation set and Held-out set
– 0.93 and 0.85, respectively – which represents an increase of
0.05 over the same results for Consensus 1.
From Table 3 we can see that the predictive performance of
our models improves the results using Consensus 2 [41] for the
RB dataset. The average NER of our models in the Validation
set is higher than that of Consensus 2 in both the Original and
Enriched versions of the dataset, and at the same time showing
more balanced Sn and Sp average values. The performance of the
model on the Held-out set is higher in the Original dataset than
in its Enriched version. Balance between Sn and Sp values is not
observed for this partition, where Sn is consistently lower than
Sp in all the experiments. It is noteworthy that this imbalance
is also present in Consensus 2, which suggests an issue with the
Held-out set data that makes prediction of inactive compounds
to be inaccurate when compared to results for the Validation
set. Nonetheless, the best trial on the Enriched version of RB,
i.e., Best_E, attained the highest NER in both Validation set and
Held-out set—0.94 and 0.89, respectively.
For both datasets CYP3A4 and CYP2C9, a high consistency is
observed between the results got for both Validation and Held-
out sets. These results show that the obtained models have strong
generalization capabilities. Besides, for both Held-out sets no
large disparity is observed between Sn and Sp values of Best_E,
which in turn implies that the proposed models are able to
classify active and inactive compounds unbiasedly. At a high-level
analysis of the results, the results for the three datasets show
that their Enriched versions lead to models with higher predictive
performance and more balanced Specificity and Sensitivity than
just using the Original versions with the descriptors chosen by
means of a feature selection approach. Attaining balanced perfor-
mance in a binary classification problem is a desirable quality in a
QSAR model [81]. The results of the Enriched models suggest that
there is relevant data encoded on molecular descriptors that were
not present in the Original versions of the datasets. Consequently,
our experimental results imply that neural networks are able to
learn in large dimensionality scenarios, and that performing a
feature selection step could lead to valuable information loss, and
hence to a decrease in the predictive performance. Furthermore,
our work proves that neural-based QSAR models are capable of
surpassing the benchmarked consensus-based models. Therefore,
the use of neural networks constitutes a strong approach for
QSAR modeling.
5.2. Embedded applicability domain technique
We proposed using an embedded AD model based on the
class probabilities calculated by the output layer of our prediction
model. This approach was applied on each QSAR model and
evaluated on the Validation and Held-out sets by measuring the
extent by which misclassification is correlated to the predicted
class confidence.
The plots for CYP2C9, which are displayed in Figs. 2 and 3,
show that as the number of compounds in the AD increases,
i.e., to the right on the horizontal axis, the values for all metrics
tend to decay continuously, which implies that the predictive
performance of the model is in fact correlated with our definition
of AD.
It is fair to say that these curves are not smooth for the
left-most compounds. Some peaks are observed in NER and Acc
plots (Figs. 2-a and 3-a), while slope fluctuations in the Sn and
Sp curves are observed (Figs. 2-b and 3-b). For the best trial
Best_E, as it can be seen from Fig. 3, a strong downward peak
is observed on the Sp curve for the left-most compounds. This
was caused by a few inactive compounds that were misclassified
with a high output probability, which is clearly an unexpected
result. It is worth noticing, however, that the curve fluctuation
stabilizes shortly after this peak is observed. Fig. 2 shows that
in average all trials exhibited similar behavior to the best trial,
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Fig. 8. Post hoc feature analysis on CYP2C9. The rows represent different trials of our model sorted by performance, and the columns represent the 20 most relevant
molecular descriptors. Both the color and the value in the cells represent the rank of a descriptor in terms of its relevance for a particular trial.
Fig. 9. Post hoc feature analysis on CYP3A4. The rows represent different trials of our model sorted by performance, and the columns represent the 20 most relevant
molecular descriptors. Both the color and the value in the cells represent the rank of a descriptor in terms of its relevance for a particular trial.
Best_E. Moreover, irregularities on the slope of Sn and Sp for
Average_E can be explained because of a few trials performing
quite poorly compared to the majority of the trials. This issue can
be examined in more detail in the Supplementary Material.
With regard to dataset CYP3A4, and similarly to what we
observed for CYP2C9, Figs. 4 and 5 show the effectiveness of
our embedded AD approach. From the analysis of the Average
performance on the Held-out set on Fig. 4, Sn exhibits a fair
variance for the left-most compounds, as depicted in its uneven
curve for NER, while Sp is smooth along the whole set. In contrast,
Best_E exhibits a fairly smooth NER curve. The irregularities on
the slope of Sn for Average_E can be explained by a few trials that
performed slightly worse than the majority of the trials.
Regarding RB (Figs. 6 and 7), Sn on both the average per-
formance plot and on the best trial plot are not smooth, as it
presents abrupt decays for the left-most compounds. Some peaks
can be observed on NER curves as well, which is caused by on
the Sn curves (Figs. 6-b and 7-b). These observations imply that
the model is not able to predict active compounds with high
certainty correctly. Even though the curves stabilize when fewer
compounds are not assigned (%na), the behavior of the best trial
appears to be unstable, even though this same model performed
outstandingly well on the Validation set. This issue, along with
the average results on the Held-out set from Fig. 6, indicates that
the model was not able to generalize well, since it exhibits a
poor performance in terms of Sn. As discussed above, imbalanced
Sn and Sp results are also observed for Consensus 2, as reported
by Mansouri et al. [41].
One possible cause for this issue might be that the compounds
in the Held-out set are significantly different from those in the
Train and Validation sets. In order to test this hypothesis, we
performed a similarity analysis between all partitions of the three
datasets using two distances: standardized Euclidean and cosine.
The results from such analysis are presented in the Supplemen-
tary Material, and they show that there is indeed a large average
difference between the compounds in the Held-out set of the
RB dataset and those in the Validation set when measuring their
respective distances to the RB Train set. These average distances
are in turn considerably larger than those observed for CYP2C9
M.V. Sabando, I. Ponzoni and A.J. Soto / Applied Soft Computing Journal 85 (2019) 105777 11
Fig. 10. Post hoc feature analysis on Ready biodegradability (RB). The rows represent different trials of our model sorted by performance, and the columns represent
the 20 most relevant molecular descriptors. Both the color and the value in the cells represent the rank of a descriptor in terms of its relevance for a particular trial.
and CYP3A4 datasets. The difference between these sets of com-
pounds would explain the generalization problems of Best_E on
RB Held-out set.
This generalization problem due to data distribution differ-
ences gets exacerbated as the dimensionality of the data in-
creases, so the models built upon the Enriched version are dis-
favored in contrast to those models for the Original version.
From the figures discussed above it is clear that our models
were able to reach the same NER values as reported by Nembri
et al. [40] and Mansouri et al. [41] for the three datasets, yet
dismissing many fewer compounds as not assigned (%na) than the
models proposed therein. For CYP2C9, a NER value of 0.83 with
45%na is reported for Consensus 1, while Best_E attains the same
NER value dismissing only 22% of compounds on the Held-out set.
In the case of CYP3A4, a NER value of 0.8 with 42%na is reported
for Consensus 1, while Best_E achieves the same NER value with
only 20%na on the Held-out set. Finally, on the Held-out set of RB
dataset, a NER value of 0.87 with 13%na is reported for Consensus
2, while Best_E attains the same NER value with only 5%na. A
similar analysis could be performed by taking into consideration
%na reported by Nembri et al. [40] and Mansouri et al. [41] for the
three datasets, since our models systematically reached higher
NER values for the same amount of discarded compounds than
Consensus 1 and Consensus 2 in both Validation and Held-out sets.
5.3. Post hoc feature analysis
From the heat maps in Figs. 8–10, one interesting aspect in
all three models is that we can pinpoint molecular descriptors
that were highly influential to all trials of the same model. For
instance, for CYP2C9, the ECFP fragment ECFP_393 was the most
relevant feature for eleven out of the fifteen trials, being nine
of those trials among the best performing ones. Molecular de-
scriptors H-046 and nRNR2 were also frequently selected in the
different trials; the latter descriptor is also present in the Original
CYP2C9 dataset. In the case of CYP3A4, the fragment ECFP_885
was a highly influential feature during the training phase of the
model, as it was considered among the top three most rele-
vant descriptors in all trials. Descriptors SdssC and H-049 were
also signaled as relevant to the majority of trials, according to
our measure. Interestingly, the molecular descriptor D/Dtr04 was
identified as an important feature occupying the first place in
five trials, although these trials were among the worst trials. For
dataset RB, the molecular descriptor NdssC is chosen as the most
relevant for most models, as it was considered the most relevant
descriptor for eleven out of the fifteen trials. Descriptors O-058
and C-040 were also signaled as important features, occupying
the top three positions for the majority of trials.
Another interesting aspect that can be observed from these
heat maps is that similarly performing trials tend to choose
the same descriptors and in similar order of relevance. For in-
stance, in Fig. 8 descriptors are: N-071, NsssCH, C-034 and H-051
were spotted as relevant only by the best performing trials and
occupied similar positions on the relevance rankings of every
trial. Similarly, SsssN, T(N..N), H-047, MLOGP2, F01[C-N] and the
P_VSA family of descriptors were deemed as influential in low-
performing trials. The ECFP fragments were mostly included by
the best-performing trials. The same phenomenon is observed in
Fig. 9: ECFP_509, ECFP_599 and ECFP_862 were mostly signaled by
our measure in the best trials, while descriptors D/Dtr05, D/Dtr11,
SAdon, SsOH, SsssN, nArOR and the P_VSA family of descriptors
were found to be somewhat relevant in the low-performing trials.
Among the molecular descriptors identified as relevant for
each model by our technique, there are some descriptors that are
also in the Original versions of the datasets. The largest number of
descriptors shared between these two sets is observed for dataset
RB, where 10 out of 36 of the features signaled as the most impor-
tant were also present in the Original RB dataset. Out of these 10,
only 4 descriptors were highly relevant to the majority of trials,
yet occupying medium-to-low importance positions in all models.
Fig. 8 shows that only 3 out of the 36 descriptors are present
in both the Original and Enriched CYP2C9 dataset; however, as
mentioned before, the descriptor nRNR2 was identified as one of
the most relevant descriptors for all of the trials by our technique.
Lastly, in Fig. 9 it is shown that no molecular descriptors present
in the Original CYP3A4 dataset were marked as relevant for the
Enriched model. It is worth noticing that both models Consensus
1 developed for CYP2C9 and CYP3A4 datasets by Nembri et al.
[40] take into account ECFP as inputs to one of their base models,
hence all of the ECFP fragments are considered to be present in
the Original version of these two datasets.
Taking into consideration that all of our models outperformed
the reference models reported by Nembri et al. [40] and Mansouri
et al. [41], while at the same time identifying relevant molecular
descriptors not included in the Original datasets, it is possible
to conclude that meaningful information for the model might be
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encoded in such molecular descriptors, and hence that relevant
data could have been lost in the Original feature selection pro-
cess. Furthermore, by means of this technique it was possible to
identify molecular descriptors that were relevant to our models,
and to find interesting relationships among them. Therefore, the
proposed technique for post hoc feature analysis represents a
way of providing interpretability to our neural-based models.
One observation of the heat map visualizations is that they are
practically limited by the maximum number of compounds that
can be visually analyzed at the same time. Yet we note that an
analysis on the top-20 or 30 features can be carried out with no
problems as it was described previously.
6. Conclusions
QSAR modeling has become a key stage in the complex drug
discovery process throughout the years. Upon the recent increase
in the volume and quality of accessible datasets as well as com-
putational power, more complex machine learning algorithms
have established as current state of the art in QSAR modeling.
Consensus approaches have consistently proven their efficacy for
bioactivity prediction, but tend to lack interpretability and suffer
from the limitations of their base classifiers. DNNs have not been
widely adopted as a standard for QSAR modeling yet, although
their effectiveness in solving high-dimensional problems make
them a suitable technique for this area.
While DNN-based models attain higher predictive
performance than other established techniques, they have their
own challenges, such as low interpretability and proneness to
overfitting. In this work we developed three neural-based QSAR
models, which outperformed the state-of-the-art results for the
three properties under study. At the same time we address
the interpretability drawback without the need for performing
feature selection. In addition, in this work we posed a strategy
for analyzing the applicability domain of a neural-based QSAR
model based on network output probabilities, which was shown
to be correlated to the likelihood of correct classification. We also
provided a technique based on an aggregation of the network
weights for identifying the most relevant molecular descriptors
and fingerprint fragments in a post hoc manner, which provides
a sense of interpretability to our models. As future work we
plan to investigate the impact of multi-task training, as a way
of improving the performance of neural-based QSAR models.
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